Study guide

16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance

APMLE Part I Basic Sciences Podiatry

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Lower Extremity Osteology

1.1 APMLE Part I Exam Structure, Policies & Scoring 1.2 Foot Osteology: Tarsals, Metatarsals, Phalanges & Sesamoids 1.3 Leg & Ankle Osteology: Tibia, Fibula & The Ankle Mortise 1.4 Pelvis, Femur & Patella Osteology: Landmarks & Biomechanics

2 Chapter 2: Lower Extremity Arthrology & Ligaments

2.1 Foot Articulations: Subtalar, Midtarsal, Lisfranc & Digital Joints 2.2 Talocrural (Ankle) & Knee Joints: Ligaments & Kinematics 2.3 Hip Joint & Pelvic Articulations: Capsular Structures & Dynamics

3 Chapter 3: Lower Extremity Myology & Compartments

3.1 Anterior & Lateral Compartments of the Leg 3.2 Superficial & Deep Posterior Compartments of the Leg 3.3 Plantar Layers & Intrinsic Musculature of the Foot 3.4 Thigh & Gluteal Musculature: Attachments & Innervations

4 Chapter 4: Lower Extremity Neurovascular & Topographical Anatomy

4.1 Lumbar & Sacral Plexuses, Peripheral Nerves & Dermatomes 4.2 Arterial Network, Venous Drainage & Lymphatics 4.3 Tarsal Tunnel, Femoral Triangle & Topographical Spaces

5 Chapter 5: Microbiology: Bacteriology, Zoonoses & Laboratory Methods

5.1 Gram-Positive Cocci & Bacilli in Podiatric Infections 5.2 Gram-Negative Bacilli & Opportunistic Pathogens 5.3 Anaerobic Pathogens & Diabetic Foot Infections 5.4 Bacterial Structure, Virulence Factors & Sterilization 5.5 Mycobacteria, Spirochetes, Mycoplasma & Zoonotic Infections 5.6 Antimicrobial Resistance, Susceptibility Testing, Specimen Handling & Vaccines

6 Chapter 6: Mycology, Virology, Parasitology & Clinical Immunology

6.1 Mycology: Dermatophytes, Onychomycosis & Systemic Mycoses 6.2 Clinically Relevant Viruses & Parasitic Infections 6.3 Innate & Adaptive Immunity Mechanisms 6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity 6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods

7 Chapter 7: General & Cellular Pathology

7.1 Cellular Injury, Adaptations & Cell Death Mechanisms 7.2 Acute vs Chronic Inflammation & Tissue Repair 7.3 Hemodynamic Disorders, Thrombosis, Embolism & Shock 7.4 Neoplasia, Oncogenes, Tumor Suppressors & Cutaneous Tumors

8 Chapter 8: Systemic & Podiatric Pathology

8.1 Atherosclerosis, Peripheral Artery Disease & Diabetic Microangiopathy 8.2 Osteoarthritis, Inflammatory Arthritides & Bone Infections 8.3 Neuropathic Disorders, Charcot Neuroarthropathy & Dermatopathology 8.4 Laboratory Diagnostics, Synovial Fluid & Biopsy Interpretation

9 Chapter 9: Organ-System Pathology

9.1 Anemias, Hemoglobinopathies, Leukemias & Immune Disorders 9.2 Cardiac & Pulmonary Pathology 9.3 Renal, Urogenital & Reproductive Pathology 9.4 Gastrointestinal, Hepatobiliary & Endocrine Pathology

10 Chapter 10: General Pharmacology, Autonomic Drugs & Toxicology

10.1 Pharmacokinetics, ADME & Receptor Dynamics 10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists 10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications 10.4 Cardiovascular Pharmacology in Podiatric Patients 10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology

11 Chapter 11: Antimicrobial & Podiatric Therapeutics

11.1 Antibacterial Classes, Mechanisms & Resistances 11.2 Antifungal, Antiviral & Antiparasitic Therapeutics 11.3 NSAIDs, Opioids, Corticosteroids & Anti-Gout Agents 11.4 Local & General Anesthetic Pharmacology

12 Chapter 12: Systemic Pharmacology

12.1 Anticonvulsants, Antidepressants, Psychotropics & Skeletal Muscle Relaxants 12.2 Insulin & Noninsulin Glycemic Agents 12.3 Respiratory & Gastrointestinal Agents 12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants 12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents

13 Chapter 13: General Anatomy: Systemic Gross Anatomy & Neuroanatomy

13.1 Cranial Nerves, Head & Neck Anatomy 13.2 Thoracic Wall, Tracheobronchial Tree, Lungs & Mediastinum 13.3 Abdominal Wall, GI Viscera, Pelvis & Retroperitoneum 13.4 Vertebral Column, Spinal Cord & Upper Extremity Overview 13.5 Neuroanatomy: CNS Organization, Somatosensory & Motor Pathways

14 Chapter 14: Histology, Integument, Embryology & Genetics

14.1 Microscopic Anatomy: Epithelia, Connective Tissue, Muscle & Nerve 14.2 Integumentary System: Dermis, Appendages, Nail Unit & Cutaneous Receptors 14.3 Embryogenesis, Limb Morphogenesis & Postnatal Development 14.4 Medical Genetics & Structural Alterations in Aging

15 Chapter 15: Cellular, Neuromuscular & Cardiovascular Physiology

15.1 Membrane Potential, Ion Channels & Transport Mechanisms 15.2 Action Potentials, Synaptic Transmission & Muscle Contraction 15.3 Cardiac Electrophysiology, ECG & Hemodynamics 15.4 Blood Pressure Regulation, Poiseuille Law & Capillary Dynamics

16 Chapter 16: Organ-System Physiology: Respiratory, Renal, Endocrine, GI & Blood

16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation 16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance 16.3 Endocrine Regulation, Reproductive Hormones, Calcium & Bone 16.4 Gastrointestinal & Hepatobiliary Physiology 16.5 Hematology: Erythropoiesis, Leukocytes, Platelets & Coagulation 16.6 Exercise Physiology, Thermoregulation & Bone Mechanobiology

17 Chapter 17: Biochemistry: Proteins, Enzymes, Carbohydrates & Signaling

17.1 Amino Acid Chemistry, Protein Structure & Enzyme Kinetics 17.2 Glycolysis, Gluconeogenesis, Glycogen Metabolism & TCA Cycle 17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors 17.4 Hormones, Receptors, Second Messengers & Signal Transduction

18 Chapter 18: Biochemistry: Lipids, Molecular Genetics, Blood Chemistry & Nutrition

18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins 18.2 Nucleotide Metabolism, DNA Replication, Transcription, Translation & Repair 18.3 Vitamins, Micronutrients & Inborn Errors of Metabolism 18.4 Blood Chemistry: Heme Metabolism, Hemoglobin & Plasma Proteins 18.5 Nutrition: Energy Balance, Glycemic Index, Fed-Fast Cycle & Free Radicals

16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance

Key Takeaways Explain This Topic AI

Glomerular Filtration Rate (GFR ~125 mL/min) is measured clinically via Inulin clearance (gold standard) or Creatinine clearance, which slightly overestimates GFR due to proximal tubular secretion; renal plasma flow (RPF ~625 mL/min) is measured by para-aminohippuric acid (PAH) clearance, yielding a normal Filtration Fraction (FF = GFR/RPF) of approximately 20%.

Glomerular hemodynamics are independently regulated at the arterioles: NSAIDs inhibit prostaglandin-mediated afferent arteriolar vasodilation, precipitating pre-renal acute kidney injury (decreased RPF and GFR), whereas Angiotensin II preferentially constricts efferent arterioles, elevating intraglomerular capillary hydrostatic pressure and filtration fraction to maintain GFR during hypoperfusion; ACE inhibitors dilate efferent arterioles, reducing proteinuria.

The Proximal Convoluted Tubule reabsorbs 65% of filtered Na+ and water isotonically, 100% of glucose (via SGLT2 up to Tm ~375 mg/min) and amino acids, and 85% of filtered HCO3- via apical NHE3 and Carbonic Anhydrase (inhibited by acetazolamide); uric acid is reabsorbed in early PCT via URAT1, which is inhibited by uricosuric agents like probenecid.

The Thick Ascending Limb reabsorbs 25% of filtered electrolytes via the apical NKCC2 cotransporter (inhibited by loop diuretics), driving medullary hypertonicity and generating a lumen-positive transepithelial potential (+8 to +10 mV) that propels paracellular Ca2+ and Mg2+ reabsorption; the Distal Convoluted Tubule NCC cotransporter is inhibited by thiazides, which enhance distal Ca2+ reabsorption through apical TRPV5 channels and basolateral NCX1.

Systemic acid-base evaluation requires calculating the Serum Anion Gap (Na+ - [Cl- + HCO3-], normal 8-12 mEq/L) and applying Winter's formula (expected PCO2 = 1.5 * HCO3- + 8 ± 2) for metabolic acidosis: High Anion Gap Metabolic Acidosis (MUDPILES: Methanol, Uremia, DKA, Propylene glycol, INH/Iron, Lactic acidosis, Ethylene glycol, Salicylates) reflects unmeasured organic anions, whereas normal anion gap acidosis reflects bicarbonate loss (diarrhea, RTAs) with hyperchloremia.

Last updated: October 2026

16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance

Independent Study Guide Notice: Independent study guide by ExamFinch. This educational resource is developed independently by ExamFinch and is not sponsored, endorsed, or affiliated with the National Board of Podiatric Medical Examiners (NBPME) or Meazure Learning.

Glomerular Filtration & Renal Hemodynamics

The kidneys maintain intravascular volume, electrolyte osmolarity, and extracellular fluid acid-base homeostasis while clearing metabolic waste products. The two kidneys receive approximately 20% to 25% of resting cardiac output , representing a Renal Blood Flow (RBF) of roughly 1.2 L/min in a healthy 70-kg adult.

Core Clearance Formulas & Equations

Renal Plasma Flow (RPF): RPF = RBF × ( 1 − Hematocrit ) \text{RPF} = \text{RBF} \times (1 - \text{Hematocrit}) RPF = RBF × ( 1 − Hematocrit ) At a normal hematocrit of 0.45, RPF = 1200 × 0.55 ≈ 660 mL/min \text{RPF} = 1200 \times 0.55 \approx 660 \text{ mL/min} RPF = 1200 × 0.55 ≈ 660 mL/min .

Renal Clearance ( C x C_x C x ​ ): The theoretical volume of plasma completely cleared of a substance x x x by the kidneys per unit time: C x = U x × V P x C_x = \frac{U_x \times V}{P_x} C x ​ = P x ​ U x ​ × V ​ Where U x U_x U x ​ is urine concentration, V V V is urine flow rate (mL/min), and P x P_x P x ​ is plasma concentration.

Measurement of Effective RPF via Para-Aminohippuric Acid (PAH):

PAH is freely filtered at the glomerulus and avidly secreted by organic anion transporters in the proximal tubule. At low plasma concentrations, PAH undergoes nearly 100% extraction (90% in single pass) from renal arterial blood.

Therefore, PAH clearance ( C P A H C_{PAH} C P A H ​ ) equals Effective Renal Plasma Flow (eRPF ~600--650 mL/min) . True RPF = C P A H 0.90 \text{RPF} = \frac{C_{PAH}}{0.90} RPF = 0.90 C P A H ​ ​ .

Measurement of Glomerular Filtration Rate (GFR):

Inulin Clearance ( C i n u l i n C_{inulin} C in u l in ​ ): Inulin is a fructose polymer that is freely filtered at the glomerulus and is neither reabsorbed, secreted, nor metabolized by the renal tubules . Consequently, inulin clearance is the undisputed gold standard for GFR (~125 mL/min, or ~180 L/day) .

Creatinine Clearance ( C C r C_{Cr} C C r ​ ): Creatinine is an endogenous breakdown product of skeletal muscle creatine phosphate. Like inulin, it is freely filtered; however, a small fraction (~10% to 20%) is actively secreted by proximal tubule cells. As a result, C C r C_{Cr} C C r ​ slightly overestimates true GFR .

Serum Creatinine vs. GFR Relationship: The relationship between serum creatinine and GFR is inverse and non-linear (hyperbolic) . GFR must drop by approximately 50% before serum creatinine rises above the normal reference range ( 0.7 – 1.2 mg/dL 0.7\text{--}1.2 \text{ mg/dL} 0.7 – 1.2 mg/dL ), making serum creatinine an insensitive marker for early renal damage.

Filtration Fraction (FF): The fraction of renal plasma flow that is filtered across the glomerular filtration barrier into Bowman's space: FF = GFR RPF ≈ 125 mL/min 625 mL/min = 0.20 (20%) \text{FF} = \frac{\text{GFR}}{\text{RPF}} \approx \frac{125 \text{ mL/min}}{625 \text{ mL/min}} = 0.20 \text{ (20\%)} FF = RPF GFR ​ ≈ 625 mL/min 125 mL/min ​ = 0.20 (20%) Glomerular Arteriolar Hemodynamics

  • AFFERENT ARTERIOLE EFFERENT ARTERIOLE
  • [Dilated by Prostaglandins] [Constricted by Angiotensin II]
  • │ ▲
  • ▼ │
  • ┌────────────────┐ ┌────────────────┐
  • │ AFFERENT │══► GLOMERULAR ══► EFFERENT │
  • │ ARTERIOLE │ CAPILLARIES │ ARTERIOLE │
  • └────────────────┘ [High P_gc] └────────────────┘
  • ▲ │ ▲
  • │ ▼ │
  • NSAIDs BLOCK Filtration Barrier ACE-I / ARBs
  • Prostaglandins (Endothelium, GBM, BLOCK Ang II
  • (Afferent Constriction) Podocytes) (Efferent Dilation)
  • > RPF drops │ -> P_gc drops
  • > GFR drops ▼ -> GFR drops
  • > FF unchanged BOWMAN SPACE -> FF drops
  • (Ultrafiltrate) -> Renal Protection
  • The Glomerular Filtration Barrier

The glomerular capillary wall consists of three anatomical layers that collectively establish a size-selective and charge-selective barrier:

Fenestrated Capillary Endothelium: Pores measuring 70 to 100 nm prevent cellular elements (erythrocytes, leukocytes, platelets) from entering Bowman's space, but allow unrestricted passage of fluid, electrolytes, and small proteins.

Glomerular Basement Membrane (GBM): Composed of a dense meshwork of Type IV collagen (specifically α 3 , α 4 , α 5 \alpha_3, \alpha_4, \alpha_5 α 3 ​ , α 4 ​ , α 5 ​ chains), laminin, nidogen, and negatively charged heparan sulfate proteoglycans . Provides a physical size sieve (excluding molecules > 4 nm >4 \text{ nm} > 4 nm ) and a formidable negative charge barrier that repels negatively charged polyanions—chiefly serum albumin (molecular radius ~3.6 nm).

Visceral Epithelial Layer (Podocytes): Epithelial cells extending interdigitating foot processes (pedicels) that wrap around glomerular capillaries. Between adjacent pedicels lie filtration slit diaphragms (~25 to 30 nm wide) composed of specialized structural proteins: nephrin , podocin, and CD2AP.

Important

Glomerular Barrier Pathology & Minimal Change Disease:

Charge Barrier Disruption: In Minimal Change Disease (Lipoid Nephrosis) , systemic T-cell cytokine release causes diffuse podocyte foot process effacement and selective enzymatic loss of negatively charged heparan sulfate from the GBM. Bereft of negative electrostatic repulsion, serum albumin freely permeates into the ultrafiltrate, producing massive selective albuminuria ( > 3.5 g/day >3.5 \text{ g/day} > 3.5 g/day ), profound hypoalbuminemia, anasarca, and hyperlipidemia.

Structural Collagen Defects: Mutations in the COL4A5 gene encoding the α 5 \alpha_5 α 5 ​ chain of Type IV collagen cause Alport Syndrome (X-linked nephritis, sensorineural deafness, and ocular lens abnormalities with characteristic irregular thinning, thickening, and "basket-weave" lamellation of the GBM). In Goodpasture Syndrome , autoantibodies target the non-collagenous domain of the α 3 \alpha_3 α 3 ​ chain of Type IV collagen, causing rapidly progressive glomerulonephritis and pulmonary alveolar hemorrhage.

Arteriolar Hemodynamics: NSAIDs vs. Angiotensin II & ACE Inhibitors

Glomerular capillary hydrostatic pressure ( P G C P_{GC} P GC ​ ) and plasma flow ( R P F RPF RPF ) are independently governed by vascular resistance in the afferent and efferent arterioles:

Hemodynamic Intervention Afferent Tone Efferent Tone Renal Plasma Flow (RPF) GFR Filtration Fraction (FF = GFR/RPF) Clinical Board Correlation

Prostaglandins ( P G E 2 , P G I 2 PGE_2, PGI_2 PG E 2 ​ , PG I 2 ​ ) Dilates Neutral / Mild Increased ( ↑ \uparrow ↑ ) Increased ( ↑ \uparrow ↑ ) Unchanged ( ↔ \leftrightarrow ↔ ) Preserves GFR during hypovolemia

NSAID Administration Constricts Neutral Decreased ( ↓ ↓ \downarrow\downarrow ↓↓ ) Decreased ( ↓ \downarrow ↓ ) Unchanged ( ↔ \leftrightarrow ↔ ) Pre-renal acute kidney injury ; acute gout risk

Angiotensin II Neutral / Mild Constricts Decreased ( ↓ \downarrow ↓ ) Maintained / ↑ \uparrow ↑ Markedly Increased ( ↑ ↑ \uparrow\uparrow ↑↑ ) Defends GFR during hypoperfusion

ACE Inhibitors / ARBs Neutral Dilates Increased / ↔ \leftrightarrow ↔ Decreased ( ↓ \downarrow ↓ ) Decreased ( ↓ ↓ \downarrow\downarrow ↓↓ ) Reduces glomerular hypertension; antiproteinuric

Ureteral Obstruction (Stone) Neutral Neutral Unchanged ( ↔ \leftrightarrow ↔ ) Decreased ( ↓ \downarrow ↓ ) Decreased ( ↓ \downarrow ↓ ) Increases Bowman hydrostatic pressure ( P B S P_{BS} P BS ​ )

Severe Dehydration (Shock) Constricts Constricts Severely Decreased ( ↓ ↓ ↓ \downarrow\downarrow\downarrow ↓↓↓ ) Decreased ( ↓ ↓ \downarrow\downarrow ↓↓ ) Increased ( ↑ \uparrow ↑ ) Prerenal azotemia: BUN / Cr > 20 : 1 \text{BUN}/\text{Cr} > 20:1 BUN / Cr > 20 : 1

Nephron Segment Transport & Diuretic Pharmacology Segmental Nephron Transport Mechanisms

  • PROXIMAL CONVOLUTED TUBULE (PCT) THICK ASCENDING LIMB (TAL)
  • 65% Na+, K+, Cl-, H2O (Isotonic) - 25% Na+, K+, 2Cl- via NKCC2
  • 100% Glucose (SGLT2), Amino Acids - Water IMPERMEABLE ("Diluting")
  • 85% HCO3- via Carbonic Anhydrase - Lumen-positive potential (+8 mV)
  • Target: ACETAZOLAMIDE (CA IV/II) drives paracellular Ca2+, Mg2+
  • URAT1: Uric acid (Probenecid target) - Target: FUROSEMIDE (Loop Diuretic)
  • ─────────────────────────────────────── ───────────────────────────────────────
  • DISTAL CONVOLUTED TUBULE (DCT) COLLECTING DUCT (CD)

- 5-10% Na+, Cl- via NCC cotransporter - PRINCIPAL CELLS:

  • Water IMPERMEABLE ENaC reabsorbs Na+; ROMK secretes K+
  • Active Ca2+ reabsorption via TRPV5 Aldosterone stimulates ENaC / Na+/K+
  • (Stimulated by PTH) ADH stimulates AQP2 insertion (V2/cAMP)
  • Target: THIAZIDES (HCTZ, Chlorthalidone) - Target: SPIRONOLACTONE, AMILORIDE

*Thiazides DECREASE urine Ca2+* - INTERCALATED CELLS (α-type):

  • H+-ATPase secretes acid, reabsorbs HCO3-
  • 1. Proximal Convoluted Tubule (PCT)

Primary Engine: Driven by the basolateral N a + / K + Na^+/K^+ N a + / K + ATPase , which pumps 3 N a + Na^+ N a + out and 2 K + K^+ K + in, maintaining a low intracellular N a + Na^+ N a + concentration ( 15 mM ~15 \text{ mM} 15 mM ) and a negative intracellular potential ( − 70 mV -70 \text{ mV} − 70 mV ).

Isotonic Reabsorption: Approximately 65% to 70% of all filtered N a + Na^+ N a + , H 2 O H_2O H 2 ​ O , K + K^+ K + , and C l − Cl^- C l − is reabsorbed here isotonically (tubular fluid osmolarity remains ~300 mOsm/kg).

Glucose and Solute Cotransport: 100% of filtered glucose and amino acids are reabsorbed in early PCT via sodium-dependent secondary active transporters: SGLT2 (apical high-capacity, low-affinity N a + Na^+ N a + -glucose cotransporter in S1 segment) and SGLT1. The tubular transport maximum ( T m T_m T m ​ ) for glucose is approximately 375 mg/min 375 \text{ mg/min} 375 mg/min . When plasma glucose exceeds 180 – 200 mg/dL 180\text{--}200 \text{ mg/dL} 180 – 200 mg/dL (the renal threshold), SGLT transporters saturate, causing glucosuria and secondary osmotic diuresis.

Bicarbonate Reabsorption & Carbonic Anhydrase: 85% of filtered H C O 3 − HCO_3^- H C O 3 − ​ is reclaimed in the PCT:

The apical N a + / H + Na^+/H^+ N a + / H + exchanger 3 (NHE3) secretes H + H^+ H + into the tubular lumen in exchange for luminal N a + Na^+ N a + .

In the lumen, secreted H + H^+ H + combines with filtered H C O 3 − HCO_3^- H C O 3 − ​ to form carbonic acid ( H 2 C O 3 H_2CO_3 H 2 ​ C O 3 ​ ).

Apical Carbonic Anhydrase IV (CA IV) rapidly dehydrates H 2 C O 3 H_2CO_3 H 2 ​ C O 3 ​ into C O 2 CO_2 C O 2 ​ and H 2 O H_2O H 2 ​ O .

C O 2 CO_2 C O 2 ​ diffuses passively across the apical membrane into the tubule cell.

Inside the cell, Cytoplasmic Carbonic Anhydrase II (CA II) hydrates C O 2 + H 2 O CO_2 + H_2O C O 2 ​ + H 2 ​ O back into H 2 C O 3 H_2CO_3 H 2 ​ C O 3 ​ , which dissociates into H + H^+ H + and H C O 3 − HCO_3^- H C O 3 − ​ .

Intracellular H + H^+ H + is recycled back into the lumen via NHE3, while H C O 3 − HCO_3^- H C O 3 − ​ is extruded across the basolateral membrane into peritubular capillaries via the N a + / H C O 3 − Na^+/HCO_3^- N a + / H C O 3 − ​ cotransporter (NBCe1) .

Acetazolamide: Selectively inhibits both CA IV and CA II. Blocks H C O 3 − HCO_3^- H C O 3 − ​ reabsorption, inducing brisk bicarbonate diuresis, urinary alkalinization ( p H > 7.5 pH > 7.5 p H > 7.5 ), and a Normal Anion Gap Hyperchloremic Metabolic Acidosis (used to treat acute mountain sickness and metabolic alkalosis).

Uric Acid Transport (Podiatric Significance): The early PCT reabsorbs over 90% of filtered urate via the apical URAT1 anion exchanger. Probenecid and sulfinpyrazone competitively inhibit URAT1, blocking urate reabsorption to promote renal uric acid excretion in chronic tophaceous gout.

2. Loop of Henle & Countercurrent Multiplication

Thin Descending Limb: Highly permeable to water via constitutive Aquaporin-1 (AQP1) channels; virtually impermeable to N a C l NaCl N a Cl and urea. As fluid descends into the hypertonic renal medulla, water exits osmotically, concentrating tubular fluid up to 1200 mOsm/kg at the hairpin bend.

Thick Ascending Limb (TAL): Completely impermeable to water ! Actively reabsorbs ~25% of filtered N a + , K + Na^+, K^+ N a + , K + , and 2 C l − 2Cl^- 2 C l − via the apical electroneutral NKCC2 cotransporter .

Lumen-Positive Transepithelial Potential: Some reabsorbed K + K^+ K + leaks back into the tubular lumen through apical ROMK (Renal Outer Medullary Potassium) channels. This retrograde positive charge leakage establishes a lumen-positive transepithelial electrical potential of + 8 to + 10 mV +8 \text{ to } +10 \text{ mV} + 8 to + 10 mV . This positive luminal voltage repels divalent cations, driving the paracellular reabsorption of Calcium ( C a 2 + Ca^{2+} C a 2 + ) and Magnesium ( M g 2 + Mg^{2+} M g 2 + ) through claudin-16/19 tight junction pores.

Loop Diuretics (Furosemide, Bumetanide, Torsemide, Ethacrynic Acid):

Reversibly inhibit the C l − Cl^- C l − binding site of the NKCC2 cotransporter .

Abolish the lumen-positive potential, blocking paracellular C a 2 + Ca^{2+} C a 2 + and M g 2 + Mg^{2+} M g 2 + reabsorption, causing hypocalcemia and hypomagnesemia ("Loops Lose Calcium").

Destroy the corticomedullary osmotic gradient, rendering the collecting duct unable to concentrate urine even in the presence of maximal ADH.

3. Distal Convoluted Tubule (DCT)

Solute Transport: Reabsorbs 5% to 10% of filtered N a + Na^+ N a + and C l − Cl^- C l − via the apical electroneutral NCC ( N a + / C l − Na^+/Cl^- N a + / C l − ) cotransporter ; completely impermeable to water ("cortical diluting segment").

Thiazide Diuretics (Hydrochlorothiazide, Chlorthalidone):

Inhibit the NCC cotransporter in the early DCT, causing mild natriuresis.

Paradoxical Calcium Retention: By inhibiting N a + Na^+ N a + entry, thiazides lower intracellular [ N a + ] [Na^+] [ N a + ] , accelerating basolateral N a + / C a 2 + Na^+/Ca^{2+} N a + / C a 2 + exchanger (NCX1) activity. This hyperpolarizes the apical membrane, opening apical TRPV5 calcium channels and markedly increasing active C a 2 + Ca^{2+} C a 2 + reabsorption. Consequently, Thiazides cause HYPOCALCIURIA and mild HYPERCALCEMIA ("Thiazides Take Calcium"), making them the drug of choice for recurrent calcium oxalate nephrolithiasis.

4. Collecting Duct: Principal vs. Intercalated Cells

Principal Cells (Sodium, Potassium & Water Regulation):

ENaC (Epithelial Sodium Channel): Apical channel that passively reabsorbs N a + Na^+ N a + down its electrochemical gradient. Basolateral N a + / K + Na^+/K^+ N a + / K + ATPase extrudes N a + Na^+ N a + and pumps K + K^+ K + in. Luminal K + K^+ K + is then secreted down its gradient through apical ROMK and BK channels.

Aldosterone Regulation: Aldosterone diffuses into principal cells, binds cytoplasmic Mineralocorticoid Receptors (MR) , translocates to the nucleus, and upregulates transcription of ENaC, ROMK, and N a + / K + Na^+/K^+ N a + / K + ATPase. Net action: Increases N a + Na^+ N a + and water retention, increases K + K^+ K + secretion and urinary excretion .

Potassium-Sparing Diuretics:

Aldosterone Antagonists (Spironolactone, Eplerenone): Competitively block MR.

ENaC Blockers (Amiloride, Triamterene): Directly plug the ENaC channel.

Both classes prevent N a + Na^+ N a + entry, abolish the negative luminal potential, and shut down K + K^+ K + secretion, causing natriuresis with hyperkalemia risk .

Antidiuretic Hormone (ADH / Vasopressin / AVP): Secreted by the posterior pituitary in response to hyperosmolarity ( > 285 mOsm/kg >285 \text{ mOsm/kg} > 285 mOsm/kg ) or hypovolemia. ADH binds basolateral V 2 V_2 V 2 ​ receptors ( G s → adenylyl cyclase → c A M P → P K A G_s \rightarrow \text{adenylyl cyclase} \rightarrow cAMP \rightarrow PKA G s ​ → adenylyl cyclase → c A MP → P K A ), triggering the exocytic insertion of Aquaporin-2 (AQP2) water channels into the apical membrane. Water is reabsorbed down the medullary osmotic gradient, producing concentrated urine (up to 1200 mOsm/kg).

Intercalated Cells (Acid-Base Regulation):

α \alpha α -Intercalated Cells (Acid Secretion): Active during systemic acidosis. Possess an apical vacuolar H + H^+ H + -ATPase and H + / K + H^+/K^+ H + / K + -ATPase that actively pump H + H^+ H + into the lumen against profound chemical gradients (dropping urine pH to 4.5). Intracellular H C O 3 − HCO_3^- H C O 3 − ​ is returned to the blood via the basolateral Anion Exchanger 1 (AE1 / C l − / H C O 3 − Cl^-/HCO_3^- C l − / H C O 3 − ​ exchanger) .

β \beta β -Intercalated Cells (Bicarbonate Secretion): Active during systemic alkalosis. Possess apical pendrin ( C l − / H C O 3 − Cl^-/HCO_3^- C l − / H C O 3 − ​ exchanger) to secrete bicarbonate into urine, and basolateral H + H^+ H + -ATPase to return H + H^+ H + to blood.

Acid-Base Physiology & Systematic Diagnostic Algorithm

Acid-base homeostasis maintains arterial extracellular pH strictly between 7.35 and 7.45 ( [ H + ] = 35 – 45 nEq/L [H^+] = 35\text{--}45 \text{ nEq/L} [ H + ] = 35 – 45 nEq/L ), regulated by the carbonic acid-bicarbonate buffer system: C O 2 + H 2 O ⇌ H 2 C O 3 ⇌ H + + H C O 3 − CO_2 + H_2O \rightleftharpoons H_2CO_3 \rightleftharpoons H^+ + HCO_3^- C O 2 ​ + H 2 ​ O ⇌ H 2 ​ C O 3 ​ ⇌ H + + H C O 3 − ​ pH = 6.1 + log ⁡ 10 ( [ H C O 3 − ] 0.03 × P a C O 2 ) \text{pH} = 6.1 + \log_{10} \left( \frac{[HCO_3^-]}{0.03 \times P_a CO_2} \right) pH = 6.1 + lo g 10 ​ ( 0.03 × P a ​ C O 2 ​ [ H C O 3 − ​ ] ​ )

The Stepwise Clinical Algorithm

Evaluate Arterial pH:

pH < 7.35 ⟹ \text{pH} < 7.35 \implies pH < 7.35 ⟹ Acidemia .

pH > 7.45 ⟹ \text{pH} > 7.45 \implies pH > 7.45 ⟹ Alkalemia .

Identify Primary Disturbance:

If acidemic and [ H C O 3 − ] < 22 mEq/L ⟹ [HCO_3^-] < 22 \text{ mEq/L} \implies [ H C O 3 − ​ ] < 22 mEq/L ⟹ Metabolic Acidosis .

If acidemic and P a C O 2 > 45 mmHg ⟹ P_a CO_2 > 45 \text{ mmHg} \implies P a ​ C O 2 ​ > 45 mmHg ⟹ Respiratory Acidosis .

If alkalemic and [ H C O 3 − ] > 26 mEq/L ⟹ [HCO_3^-] > 26 \text{ mEq/L} \implies [ H C O 3 − ​ ] > 26 mEq/L ⟹ Metabolic Alkalosis .

If alkalemic and P a C O 2 < 35 mmHg ⟹ P_a CO_2 < 35 \text{ mmHg} \implies P a ​ C O 2 ​ < 35 mmHg ⟹ Respiratory Alkalosis .

Assess Adequacy of Compensation:

The body never overcompensates; compensation moves pH toward, but does not fully reach, 7.40.

If Metabolic Acidosis, ALWAYS Calculate the Serum Anion Gap: Anion Gap = [ N a + ] − ( [ C l − ] + [ H C O 3 − ] ) \text{Anion Gap} = [Na^+] - ([Cl^-] + [HCO_3^-]) Anion Gap = [ N a + ] − ([ C l − ] + [ H C O 3 − ​ ])

Normal Serum Anion Gap: 8 to 12 mEq/L 8 \text{ to } 12 \text{ mEq/L} 8 to 12 mEq/L (reflects unmeasured polyanions, primarily albumin: ∼ 2.5 mEq/L \sim 2.5 \text{ mEq/L} ∼ 2.5 mEq/L per 1 g/dL 1 \text{ g/dL} 1 g/dL of albumin). Diagnostic Tree for Metabolic Acidosis

  • METABOLIC ACIDOSIS
  • (pH < 7.35, HCO3- < 22)
  • │
  • Calculate Serum Anion Gap
  • [Na+] - ([Cl-] + [HCO3-])
  • │
  • ┌───────────────────┴───────────────────┐
  • ▼ ▼
  • ELEVATED ANION GAP (>12) NORMAL ANION GAP (8-12)
  • [MUDPILES / GOLDMARK] [Hyperchloremic Acidosis]
  • Methanol (Formic acid) - Severe Diarrhea (loss of HCO3-)

- Uremia (Renal Failure) - Renal Tubular Acidosis (RTA):

  • Diabetic Ketoacidosis (DKA) * Type 1: Distal (H+ secretion fail)
  • Propylene glycol * Type 2: Proximal (HCO3- wasting)
  • Iron / Isoniazid * Type 4: Hypoaldosteronism (High K+)
  • Lactic Acidosis (Shock, Sepsis) - Acetazolamide (CA inhibition)
  • Ethylene Glycol (Oxalate crystals) - Normal Saline (0.9% NaCl infusion)
  • Salicylates (Aspirin Toxicity) ─────────────────────────────────
  • Calculate Urine Anion Gap (UAG)
  • [Na+]u + [K+]u - [Cl-]u
  • Negative: GI loss (Diarrhea)
  • Positive: Renal loss (RTA Type 1)
  • Metabolic Acidosis Compensation: Winter's Formula

In metabolic acidosis, respiratory compensation occurs immediately via peripheral chemoreceptor stimulation, driving hyperventilation (Kussmaul breathing) to blow off C O 2 CO_2 C O 2 ​ . Expected compensation is calculated using Winter's Formula : Expected P a C O 2 = 1.5 × [ H C O 3 − ] + 8 ± 2 \text{Expected } P_a CO_2 = 1.5 \times [HCO_3^-] + 8 \pm 2 Expected P a ​ C O 2 ​ = 1.5 × [ H C O 3 − ​ ] + 8 ± 2

If Measured P a C O 2 = Expected P a C O 2 P_a CO_2 = \text{Expected } P_a CO_2 P a ​ C O 2 ​ = Expected P a ​ C O 2 ​ : Adequate, pure respiratory compensation.

If Measured P a C O 2 > Expected P a C O 2 P_a CO_2 > \text{Expected } P_a CO_2 P a ​ C O 2 ​ > Expected P a ​ C O 2 ​ : Inadequate hyperventilation; signifies a concomitant Primary Respiratory Acidosis (e.g., DKA patient with severe respiratory depression or impending fatigue).

If Measured P a C O 2 < Expected P a C O 2 P_a CO_2 < \text{Expected } P_a CO_2 P a ​ C O 2 ​ < Expected P a ​ C O 2 ​ : Excessive hyperventilation; signifies a concomitant Primary Respiratory Alkalosis (e.g., salicylate overdose or sepsis).

High Anion Gap vs. Normal Anion Gap Etiologies

High Anion Gap Metabolic Acidosis (HAGMA): Unmeasured organic anions accumulate, replacing bicarbonate while chloride remains normal:

M ethanol: Ingestion of windshield wiper fluid; metabolized by alcohol dehydrogenase to formic acid , causing optic disc hyperemia and "snowfield blindness".

U remia: Advanced renal failure ( G F R < 15 – 20 mL/min GFR < 15\text{--}20 \text{ mL/min} GFR < 15 – 20 mL/min ); failure to excrete organic phosphates, sulfates, and urate.

D iabetic Ketoacidosis (DKA): Absolute insulin deficiency triggers uninhibited lipolysis, generating acetoacetate and β \beta β -hydroxybutyrate.

P ropylene Glycol: Solvent for IV lorazepam/diazepam; metabolized to lactic acid.

I ron / Isoniazid.

L actic Acidosis: Tissue hypoperfusion (hypovolemic, cardiogenic, or septic shock) or metformin accumulation halting oxidative phosphorylation.

E thylene Glycol: Ingestion of antifreeze; metabolized to glycolic and oxalic acid , producing acute oliguric acute tubular necrosis, marked hypocalcemia, and pathognomonic envelope-shaped calcium oxalate crystals in urine sediment.

S alicylates (Aspirin): Classic Mixed Acid-Base Disorder : direct stimulation of the medullary respiratory center induces immediate Primary Respiratory Alkalosis , while uncoupling of oxidative phosphorylation generates ketoacids and lactic acid, producing a concurrent Primary High Anion Gap Metabolic Acidosis .

Normal Anion Gap Metabolic Acidosis (NAGMA / Hyperchloremic): Bicarbonate is lost directly from the GI tract or kidneys. To maintain electroneutrality, the kidneys reabsorb chloride, resulting in hyperchloremia ( [ C l − ] > 108 mEq/L [Cl^-] > 108 \text{ mEq/L} [ C l − ] > 108 mEq/L ).

Diarrhea: Stool fluid is rich in H C O 3 − HCO_3^- H C O 3 − ​ and K + K^+ K + ; massive diarrhea produces NAGMA with hypokalemia.

Renal Tubular Acidosis (RTA):

Type 1 (Distal) RTA: Inability of α \alpha α -intercalated cells to secrete H + H^+ H + via apical H + H^+ H + -ATPase. Urine pH is persistently > 5.5 > 5.5 > 5.5 despite systemic acidemia; associated with hypokalemia, calcium phosphate nephrolithiasis, and nephrocalcinosis.

Type 2 (Proximal) RTA: Inability of PCT to reabsorb H C O 3 − HCO_3^- H C O 3 − ​ (often part of Fanconi syndrome). Urine pH variable; hypokalemia, osteomalacia, no nephrolithiasis.

Type 4 (Hyperkalemic) RTA: Aldosterone deficiency or resistance (diabetic nephropathy, NSAIDs, ACE inhibitors). Impaired distal N a + Na^+ N a + reabsorption and K + / H + K^+/H^+ K + / H + excretion ⟹ \implies ⟹ HYPERKALEMIA with urine p H < 5.5 pH < 5.5 p H < 5.5 .

Metabolic Alkalosis: Saline-Responsive vs. Saline-Resistant

Metabolic alkalosis ( p H > 7.45 , [ H C O 3 − ] > 26 pH > 7.45, [HCO_3^-] > 26 p H > 7.45 , [ H C O 3 − ​ ] > 26 ) is evaluated clinically by measuring Urine Chloride ( [ C l − ] u [Cl^-]_u [ C l − ] u ​ ) :

Saline-Responsive ( [ C l − ] u < 20 mEq/L [Cl^-]_u < 20 \text{ mEq/L} [ C l − ] u ​ < 20 mEq/L ): Characterized by extracellular volume depletion, hypochloremia, and secondary hyperaldosteronism. Etiologies: vomiting / nasogastric suction (loss of gastric H C l HCl H Cl ) or prior diuretic therapy (loop/thiazides). Infusion of isotonic normal saline (0.9% NaCl) restores intravascular volume and chloride, enabling the kidneys to excrete excess bicarbonate, curing the alkalosis.

Saline-Resistant ( [ C l − ] u > 20 mEq/L [Cl^-]_u > 20 \text{ mEq/L} [ C l − ] u ​ > 20 mEq/L ): Characterized by normovolemia or hypervolemia with autonomous mineralocorticoid excess: Primary Hyperaldosteronism (Conn syndrome) , Cushing syndrome, or genetic channelopathies (Bartter, Gitelman, Liddle syndromes). Unresponsive to saline infusion; requires mineralocorticoid receptor antagonism or surgical excision.